Dosing & Uses
Dosage Forms & Strengths
Indicated for xerostomia in patients with Sjogren's syndrome
30 mg PO q8hr
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Upper respiratory infection (11%)
Hot flashes (2%)
Abdominal pain (8%)
Excessive salivation (2%)
Urinary tract infection (6%)
Back pain (5%)
Skeletal pain (3%)
Frequency Not Defined
Uncontrolled asthma, conditions in which miosis is undesirable (eg, narrow-angle glaucoma, acute iritis)
Use caution in controlled asthma, chronic bronchitis, COPD, history of nephrolithiasis
Excessive sweating may lead to dehydration
May cause decreased visual acuity
Use caution in patients with history of billiary stones
Use caution in patients with cardiovascular disease
Pregnancy & Lactation
Pregnancy Category: C
Lactation: unknown whether distributed into breast milk, avoid or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Muscarinic receptor agonist (quinuclidine derivative of acetylcholine), exhibits high binding affinity for muscarinic M3 receptors on lacrimal & salivary gland epithelium: increases salivation
Bioavailability: Rapid absorption, food decrease rate of absorption
Peak Plasma Time: 1.5-2 hr
Protein Bound: <20%
Vd: 6 L/kg
Metabolized by CYP3A4 and CYP2D6
Metabolites: Cis- & trans-sulfoxide (inactive), glucuronic acid conjugate (inactive), N-Oxide (inactive)
Half-Life: ~5 hr
Excretion: Urine 97%; feces 0.5%
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.